HKI-272 Ketoconazole Drug Interaction Study
Information source: Wyeth
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Healthy
Intervention: HKI-272 (Drug)
Phase: Phase 1
Status: Completed
Sponsored by: Wyeth Official(s) and/or principal investigator(s):
Medical Monitor, Study Director, Affiliation: Wyeth
Summary
To investigate a potential pharmacokinetic drug interaction between HKI-272 and ketoconazole
when co-administered.
Clinical Details
Official title: An Open-Label, Randomized, 2-Period Crossover, Drug Interaction Study to Evaluate the Potential Pharmacokinetic Interaction Between Multiple Doses of Ketoconazole and a Single Dose of HKI-272 Administered Orally to Healthy Subjects
Study design: Treatment, Randomized, Open Label, Uncontrolled, Crossover Assignment
Primary outcome: Pharmacokinetics; safety and tolerability
Eligibility
Minimum age: 18 Years.
Maximum age: 50 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Healthy as determined by the investigator on the basis of medical history, physical
examination, clinical laboratory test results, vital signs, and 12-lead ECG.
Locations and Contacts
Additional Information
Starting date: October 2006
Ending date: October 2006
Last updated: December 7, 2006
|
